Could a vibrating mesh nebuliser help clear airways in Long-Term tracheostomy patients?

NCT ID NCT06834581

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This pilot study tests whether a vibrating mesh nebuliser works better than a standard jet nebuliser for people who need long-term breathing support through a tube in their windpipe (tracheostomy). The trial will measure how well the lungs work, how easily mucus is cleared, and how breathless patients feel. Twelve adults who are already on a ventilator for at least 6 hours a day will try both devices in random order for 30 hours each.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vibrating mesh nebuliser
What this could lead to
If effective, vibrating mesh nebulisers could become a standard way to deliver inhaled medications and clear mucus in people who need long-term breathing support through a tracheostomy.
What could go wrong
This is a very small pilot study with only 12 participants, so results may not apply to all tracheostomy patients. The crossover design is short (30 hours per device), so longer-term benefits or risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving long-term tracheostomy ventilation as inpatients of the Lane Fox Respiratory Service at Guy's and St Thomas' NHS Foundation Trust * Requiring prolonged mechanical ventilation for at least 6 hours per day for at least 21 days * Has a cuffed tracheostomy in situ * Aged 18-80 years old * Receiving normal (0.9%) saline or hypertonic saline nebulisation at the time of enrolment into the study * Requiring and tolerating tracheal suctioning for secretion management * Able to communicate symptom burden to the research team * Able to give informed consent for participation in the study * Clinical stability, with no requirement for changes in ventilatory support, as assessed by the responsible clinician for at least 48 hours prior to enrolment in study Exclusion Criteria: * Severe, non-respiratory organ dysfunction including, but not limited to: * Congestive cardiac failure * Cardiac arrhythmia * End-stage malignancy * End-stage renal failure * Acute pulmonary pathology requiring emergency treatment including, but not limited to: * Ventilator associated pneumonia at the time of screening * Pneumothorax * Pulmonary embolism * Severe cognitive impairment * Psychosocial factors that would preclude completion of the study protocol * Previous intolerance of aerosolised hypertonic 3% saline or nebulised salbutamol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long-term tracheostomy ventilated patients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lane Fox Unit, St Thomas' Hospital

    London, London, SE1 7EH, United Kingdom